Genentech announced that its Phase III HAVEN 3 study of Hemlibra in adults and adolescents with hemophilia A without inhibitors to factor VIII had positive results.
Source: BioSpace
Genentech announced that its Phase III HAVEN 3 study of Hemlibra in adults and adolescents with hemophilia A without inhibitors to factor VIII had positive results.
Source: BioSpace